Opioid Diversion, Postal Carrier Dangers Among Industry Concerns With Mail-Back Envelope Requirement
Executive Summary
Brand and generic drug sponsors also tell the US FDA that there are environmental considerations for providing a pre-paid mail-back envelope so patients can send unused opioids for disposal.
You may also be interested in...
New Opioid Approval Standard Intended To Drive Development Into Other Therapeutics
US FDA explored whether existing law allowed for the higher standard, but determined new authority granted by Congress was necessary.
Opioid Approval Standards Could Change Under New US FDA Plan
The Overdose Prevention Framework includes considering whether FDA should require new opioids show superior safety compared to existing products.
Coming Soon: New US FDA Opioid Plan
Commissioner Robert Califf said the new plan should be released in August and include prongs to continue fighting the ongoing prescription opioid epidemic, as well as confront a new synthetic fentanyl and methamphetamine problem.